Korro announces selection of its first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (aatd)

Cambridge, mass., dec. 07, 2023 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, krro-110, for the potential treatment of aatd. krro-110 is a proprietary rna editing oligonucleotide delivered to liver cells using clinically validated lnp technology licensed from genevant. krro-110 is designed to co-opt an endogenous enzyme adenosine deaminase acting on rna (adar) to repair a pathogenic single nucleotide variant (snv) on rna and restore production of normal a1at. preclinical development of krro-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024.
KRRO Ratings Summary
KRRO Quant Ranking